Press Releases

Date Title
Feb 24, 2022 Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative (READDI) at the University of North Carolina-Chapel Hill, Announces Late-Breaking Oral Presentation at International Conference on Antiviral Research
CMX521 Significantly Reduced Lung Viral Titer and Clinical Symptoms in a SARS-CoV-2 Mouse Model DURHAM, N.C. , Feb. 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), in collaboration with the Rapidly Emerging Antiviral Drug Development Initiative at the University of North Carolina at Chapel
Feb 22, 2022 Chimerix to Report Fourth Quarter and Year End 2021 Financial Results and Provide an Operational Update on March 1, 2022
DURHAM, N.C. , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio
Jan 20, 2022 Chimerix to Present at B. Riley Virtual Oncology Conference
DURHAM, N.C. , Jan. 20, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced Mike Andriole , Chief Business and Financial Officer,
Jan 18, 2022 Chimerix Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research
DURHAM, N.C. , Jan. 18, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that a peer-reviewed article entitled, “Phase 2 Study of
Jan 03, 2022 Chimerix to Present at Virtual H.C. Wainwright BioConnect 2022 Conference
DURHAM, N.C. , Jan. 03, 2022 (GLOBE NEWSWIRE) -- Chimerix  (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Company management, including Mike Sherman , Chief
Displaying 11 - 15 of 15
  • Print
  • Email Alerts
  • RSS Feeds
  • Search
  • Share